Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
If combining with an active treatment, timing recommendations should come from your provider
University of Pennsylvania
Macular Degeneration IV Treatments Macular degeneration intravenous treatment is a specialized approach to supporting eye health and potentially slowing vision deterioration in individuals diagnosed with macular degeneration
Limited data exists for: Understudied Populations: Adults over 75 years (increased sensitivity to appetite suppression) Adolescents (ongoing development considerations) Individuals with BMI under 27 (insufficient safety data) Pregnant or lactating individuals (no safety data) Individuals with significant psychiatric conditions Gender Considerations: Research suggests some metabolic peptides may show differential effects between males and females, though data for cagrilintide and retatrutide specifically remains limited
US$ 27.01
US$ 23.59
US$ 27.98
US$ 23.51
US$ 25.33
US$ 28.35
